Treatment adherence
How might atropine slow experimental myopia?
Open access · cc by · source: Europe PMC
In form-deprived mice, atropine drops cut axial elongation and ECM remodeling, restored choroid/sclera thickness and CVI, lowered HIF-1α, and protected hypoxic scleral fibroblasts via P53/β-catenin pathways.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Study at a glance
- Design
- Animal / in-vitro — Form-deprivation myopia in C57BL/6 mice ± 10 mg/mL atropine drops TID; plus hypoxic MSF culture with Na2S2O4 then atropine
- N
- N=16 · N=4 mice per group × 4 groups (mock, atropine, FDM, FDM+atropine); in-vitro MSFs additional
- Population
- Male C57BL/6 mice (3 weeks) with monocular form deprivation and primary mouse scleral fibroblasts
- Outcome
- Axial length, ECM/collagen, choroid/sclera thickness, CVI, HIF-1α, and fibroblast signaling
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
How might atropine slow experimental myopia?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
Four groups with N=4 mice each received saline or 10 mg/mL atropine.
4) FDM + Atropine group: covered eye treated with 10 mg/mL atropine ( N = 4 per group).
Sample size targeted 80% power for a large effect (d=2.1) at α=0.05.
The sample size of four mice per group was determined based on a power analysis (GPower 3.1.9.7) to detect a large effect size (d = 2.1) with 80% power at α = 0.05, consistent with prior studies using the FDM model
Key findings
Atropine reduced FDM axial elongation and scleral collagen-volume-fraction remodeling, restored choroidal and scleral thickness, increased CVI (central/intermediate), reduced HIF-1α, and in vitro preserved fibroblast cytoskeleton while modulating P53 and β-catenin.
Methodology
Covered one eye of 3-week C57BL/6 males (N=4/group) and gave saline or 10 mg/mL atropine TID for 21 days; measured ocular morphology, CVF, CVI, and ECM/HIF-1α. In vitro, MSFs were made hypoxic with Na2S2O4 then treated with atropine.
Limitations
N=4/group is small; 10 mg/mL in mice is not the 0.01% pediatric drop used clinically, and human choroidal-flow causality is not proven here.
Related papers in this topic
Same topic cluster — not a recommendation engine.